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doi:10.1016/j.ejvs.2008.06.012Abstract Purpose: To investigate the usefulness of greater saphenous vein preservation for
future vascular reconstructions during femoro-popliteal bypass surgery.
Design: Post-hoc analysis of data acquired in a randomized multi-centre clinical trial compar-
ing two different vascular prostheses (ClinicalTrials.gov ID: NCT 00523263).
Patients and methods: The true frequency of ipsilateral saphenous vein use in subsequent
femoro-popliteal and coronary bypass surgery was investigated through case-record analysis
with a median follow-up of 60 months in 100 consecutive patients, that received a prosthetic
femoro-popliteal bypass between 1996 and 2001.
Results: An ipsilateral secondary femoro-popliteal bypass was performed in 11 patients (11%)
at a mean interval of 34 months (range 1e96). The ipsilateral saphenous vein was applied for
these procedures in 8 cases (8%). The cumulative probability of receiving a subsequent bypass
was 8% at 3 years and 10% at 5 years follow-up respectively. One patient (1%) underwent CABG
at 8 years follow-up with the use of ipsilateral lower leg saphenous vein segments only.
Conclusion: Preservation of the greater saphenous vein in supragenicular femoro-popliteal
bypass surgery is not a valid argument for application of prosthetic material.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
The greater saphenous vein (SV) is considered the gold
standard in graft material for femoro-popliteal bypassder Vliet, MD, 690 Heelkunde,
ijmegen, The Netherlands.
0501.
.umcn.nl (J.A. van der Vliet).
ty for Vascular Surgery. Publishesurgery with the distal anastomosis above and below the
knee.1 The genuine endothelial lining and autologous
nature of the graft reduce thrombogenicity and postopera-
tive morbidity, such as graft occlusion and infection.2 The
superiority of the SV for bypass surgery below the knee
has not been subject of controversy. Prosthetic grafts
such as polytetrafluoroethylene, knitted polyester (Dacron)
and human umbilical vein are mainly recommended for by-
passes with the distal anastomosis above the knee.3 Gener-
ally, synthetic material is applied only when the SV isd by Elsevier Ltd. All rights reserved.
Table 1 Co-morbidity in 100 patients receiving a femoro-
popliteal bypass
Co-morbidity
Patients (n) 100
- DM
- Smoking
- Hyperlipidemia
- Angina/MI
- Stroke
- Hypertension
- Hyperhomocysteinemia
34%
45%
36%
28%
14%
55%
3%
DM: Diabetes Mellitus, MI: Myocardial Infarction.
VSM Preservation for Future use 421inadequate, absent or meant to be preserved for future
coronary or more distal reconstructive arterial surgery
and when alternative endovascular options or procedures
such as endarterectomy of the superficial femoral artery
are not feasible.4e7
The SV is easily harvested and a common autogenous
source for coronary artery bypass grafting (CABG) and patch
closure following carotid endarterectomy.8e10 Also, the
vein is often addressed for a secondary femoropopliteal by-
pass when a prosthetic graft fails.6 This may constitute
a reason to preserve the SV during femoro-popliteal bypass
surgery for future use. However, no explicit evidence sup-
ports the appropriateness of this regimen.
The aim of the present study was to investigate the
extent of future ipsilateral SV use in patients with a pros-
thetic femoro-popliteal bypass.
Patients and Methods
The study population consisted of the first 100 consecutive
patients with a completed follow-up, who received a fem-
oro-popliteal bypass for chronic lower extremity ischaemia
in a prospective randomized controlled clinical trial (Clin-
icalTrials.gov ID: NCT00523263) comparing two different
vascular graft prosthetic materials between 1996 and
2001.11 A case-record analysis was carried out to determine
the true frequency of ipsilateral SV use for subsequent
femoro-popliteal or coronary bypass surgery.
Femoro-popliteal bypass was defined as the insertion of
a bypass graft with the proximal anastomosis above the
adductor canal to the common-, profunda- or superficial
femoral artery and distal to the popliteal artery above or
below the knee. All patients received a prosthetic bypass
irrespective of SV presence or adequacy with either human
umbilical vein (Dardik, Biograft, Bio-Vascular, Inc., Saint-
Paul, MN) (nZ 53) or heparin-bonded collagen coated poly-
ester (Dacron, Intergard, Intervascular, Inc., La Ciotat,
France) (nZ 47).
Inclusion criteria for male and female patients were: age
31e89, chronic lower extremity ischaemia and an ankle-
brachial index below 0.8 at rest. Exclusion criteria were:
non-elective surgery, life expectancy below 2 years and
contra-indicatios for anticoagulant therapy. The standards
for reporting lower extremity ischemia were implemented
in this study.12 Critical limb ischemia was defined as ische-
mic rest pain and/or tissue loss combined with an ankle
pressure <60 mmHg with flat or barely palpable pulsations
at the ankle or metatarsals. Preoperatively, we scrutinized
patient history and cardiovascular risk factors. Patient co-
morbidity is listed in Table 1.
Physical examinations, standard treadmill walking tests
and calibrated angiography of the affected extremity were
performed. Pre-operative duplex mapping of the ipsi- and
contralatral SV was not carried out routinely. The patient
population had a median age of 67 years (range 42e88) at
the time of the initial bypass operation and 69 patients
(69%) were of male gender. The median preoperative
ipsilateral ankle-brachial index was 0.56 (range 0.16e
0.80). Pre-operative median Rutherford classification was
4 (range 1e6). Critical limb ischemia was recorded in 40
patients (40%), including 19 patients (19%) who suffered
minor tissue loss and 1 patient (1%) who suffered majortissue loss. The mean number of patent crural arteries was
2. A supragenicular bypass was performed in 94 patients
(94%). Postoperatively, patients were randomized to
receive life-long treatment by either acetylsalysilic acid
(Aspirin) 80 mg daily or coumarin derivates (Sintrom) [tar-
get INR ratio 3.0e4.5], in accordance to local treatment
protocols. Patient follow-up visits were at 3 monthly inter-
vals during the first postoperative year and yearly thereaf-
ter. The study was approved by the local Institutional
Review Board and fully informed consent, given in writing,
was obtained from all patients.
Statistical analysis
Yearly cumulative probability of receiving a subsequent
femoro-popliteal bypass or CABG was calculated by life
table analysis. Freedom of subsequent ipsilateral SV use,
graft patency and limb salvage rates were assessed by the
Kaplan-Meier method.
Results
Overall primary and secondary prosthetic femoro-popliteal
bypass patency rates were 79%, 66%, 58% and 82%, 72%, 61%
respectively at 1, 3 and 5 years follow-up. The cumulative
limb salvage rate 5 years postoperatively was 89%. The
cumulative mortality rate was 13% at 5 years.12
Previous SV use
The ipsilateral SV had been removed for vascular recon-
structive purposes in 7 cases (7%) prior to the initial femoro-
popliteal bypass operation. These cases involved CABG
procedures. No SV were used for previous femoro-popliteal
bypass surgery and none were removed in the treatment of
varicosis.
Secondary femoro-popliteal bypass
An ipsilateral secondary femoro-popliteal bypass was per-
formed in 11 patients (11%) at a mean interval of 34 months
(range 1e96). The cumulative probability of receiving
a subsequent bypass after initial femoro-popliteal recon-
struction was 8% at 3 years and 10% at 5 and 8 years follow-
up respectively. The SV was considered unfit for the
422 M. Dirven et al.procedure in one case (1%), necessitating implantation of
a prosthetic bypass. The contralateral SV was applied for
femoro-popliteal bypass in one patient and a combined
Dacron-venous bypass was inserted using the contralateral
SV in another. The ipsilateral SV was actually used for
a secondary femoro-popliteal bypass in the remaining 8
cases (8%) (Fig. 1).
CABG
One patient (1%) underwent CABG at 8 years follow-up.
Only ipsilateral lower leg SV segments were addressed for
this procedure. Cumulative probability of CABG perfor-
mance after a femoro-popliteal bypass was 0% at 3 and 5
years follow-up and 1% at 8 years follow-up.
Discussion
Vascular surgeons prefer the SV as a conduit for femoro-
popliteal bypass surgery. The vein provides superior long-
term patency and limb salvage rates. SV primary patency
rates vary from 59% to 77% at five years follow-up.4 Johnson
and co-workers described patency rates of 73%, 53% and 39%
for SV, human umbilical vein and polytetrafluoroethylene at
5 years follow-up in a large prospective trial.13 Compared to
prosthetic graft implantation, fewer re-operations are
required.14,15 Graft infections are rare in SV bypasses and
less wound morbidity is noted.2,16 A minor disadvantage of
SV use is a significantly longer operating time compared to
the application of prosthetic grafts.4 Furthermore, harvest-
ing the SV implies more extensive surgical dissection and
sacrifice of the largest superficial venous conduit. Fortu-
nately, the vein accounts for only 5e10% of the total venous
reflow, therefore excision seldom causes difficulty and sub-
sequent reconstructive surgery is rarely required.5100806040200
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Figure 1 Freedom of ipsilateral SV use after prosthetic
femoro-popliteal bypass (Kaplan-Meier analysis).A prosthetic graft is implanted to bypass the femoro-
popliteal trajectory when the SV is inadequate, absent or
meant to be preserved. Currently polytetrafluoroethylene
predominates, presumably because the material is easily
implanted and is associated with relatively low rates of
postoperative failure and wound complications.16 Experi-
ence with grafts with heparin-bonded technology is also
accumulating.11,17
The rationale behind SV preservation is a general con-
cern that patients who require a femoro-popliteal bypass
suffer concurrent coronary and carotid arterial disease.13
The SV is considered conduit source of autogenous material
for CABG and patch closure following carotid endarterec-
tomy. However, feasible alternatives are available for these
procedures. The left internal thoracic artery and mammary
artery are widely applied for CABG, as well as the radial and
gastroepiploic arteries. Additionally, advanced percutane-
ous revascularization techniques are rapidly developing.8
Goldman and co-workers specified no difference in perio-
perative mortality, morbidity and recurrent stenosis rates
between the SV, internal jugular vein and knitted Dacron
as patch materials for carotid endarterectomy.9 Further-
more, patch closure requires only a small SV segment.
Such a segment can frequently be obtained from SV sites
other than the proximal part.
The profound grades of lower extremity ischemia and
the co-morbidity in femoro-popliteal bypass patients are
most likely associated with a higher incidence of graft
failure.5 Ischemic symptoms such as claudication or tissue
loss may rapidly reoccur after graft occlusion.18 Conse-
quently, secondary femoro-popliteal reconstruction might
be needed for limb salvage. An increasing number of pa-
tients require such a redo-operation. The SV is the most
suitable graft for this type of surgery due to its length
and diameter compatibility with the tibial arteries, espe-
cially when used in an in-situ fashion.14 One might argue
that in absence or inadequacy of the ipsilateral SV, the con-
tralateral vein is available in many patients and may serve
equal purposes in femoro-popliteal bypass surgery. Some
even suggest the contralateral vein as the conduit of first
choice in such situations.19 An additional groin wound and
prolonged operation time are thereby unavoidable.4
An appropriate assessment of subsequent vascular re-
constructions is essential if one is to determine whether SV
preservation is warranted in femoro-popliteal bypass sur-
gery. The present study analyzed patients who received
a prosthetic bypass mostly with the distal anastomosis
above the knee (94%). The ipsilateral SV was therefore
present in the majority of patients (93%) and available for
additional proximal or distal vascular reconstructions.
CABG was performed prior to the initial femoro-popliteal
bypass surgery in 7% of our patients. The ipsilateral SV was
harvested for these procedures. Chew and co-workers
determined that 46% of their patients had received CABG
prior to femoro-popliteal bypass surgery.20 Biancari and co-
workers observed a 8.5% rate of vascular procedures for
lower limb ischemia during a follow-up of 7 years of 1300
patients after CABG.21These observations may indicate
that coronary arterial disease requires earlier intervention
than arteriosclerotic lesions in the lower extremities.
Few trials have investigated the need for vascular
reconstructions after femoro-popliteal bypass surgery in
VSM Preservation for Future use 423the past. In 1984 Houser and co-workers addressed the
occurrence of CABG and found that 5.4% of 74 patients
required additional coronary reconstruction.22 Poletti and
co-workers analyzed a series of 440 infrainguinal bypass pa-
tients in 1998. The probability of receiving subsequent fem-
oro-popliteal bypass or CABG was 27% and 2% respectively
at 5 years follow-up.23 The investigators did not distinguish
between SV and alternative vein sites for secondary fem-
oro-popliteal reconstruction. Both studies are retrospective
evaluations of data acquired more than 10 years ago. Our
results suggest a 10% cumulative probability of receiving
a secondary femoro-popliteal bypass 5 years postopera-
tively. Burger and co-workers prospectively compared re-
versed SV to polytetrafluoroethylene for femoro-popliteal
bypass surgery in 136 cases. The preserved veins were
used for secondary femoro-popliteal reconstruction in 2%
of the cases. No patients required the SV for CABG in the
2 year follow-up period.4 In the present study, the ipsilat-
eral SV was addressed for secondary femoro-popliteal by-
pass surgery in 8% of the patients. Only one patient
underwent CABG at 8 years follow-up. Although adequate,
the ipsilateral SV was not addressed for this procedure.
Herewith the prevalence of secondary femoro-popliteal
bypass surgery and CABG proved to be quite low in our
population. Most secondary femoro-popliteal bypasses
were performed within 3 years postoperatively. Thus, it
appears that few patients would benefit from SV preserva-
tion. Therefore, at present, we do not consider SV preser-
vation a valid argument for application of prosthetic
material in femoro-popliteal bypass surgery.
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